

The United Kingdom

and the Global Fund to Fight AIDS, Tuberculosis and Malaria


The United Kingdom's bold and longstanding support to the Global Fund has played a critical role in fighting AIDS, tuberculosis (TB) and malaria and ensuring a healthier, safer and more equitable future for all.

The Global Fund has saved 70 million lives since 2002.

The Global Fund has disbursed nearly US\$70 billion in more than 100 low- and middle-income countries since 2002 to fight AIDS, TB, and malaria, strengthen health systems and build pandemic preparedness.

Over half of our funding is dedicated to saving lives in Commonwealth countries, and 73% of our investments go towards countries in sub-Saharan Africa. With contributions from governments, foundations and the private sector, the Global Fund equitably and efficiently allocates funding to implementing countries, taking into account each country's income level and disease burden. In the countries where we invest, the Global Fund partnership has reduced the combined death rate from AIDS, TB and malaria by 63% since 2002.


Percentage of international financing provided by the Global Fund in 2024



Our partnership

The UK is the third largest donor to the Global Fund and has contributed more than GBP 5.6 billion to date. The United Kingdom is co-hosting the Global Fund's Eighth Replenishment in partnership with the Republic of South Africa, bringing governments, private sector partners and civil society together to raise the resources needed to support the Global Fund's lifesaving work. With the UK's support, the Global Fund works with local partners to strengthen health systems, advance gender equity and human rights, and protect global health security.

Pledges and contributions made by the United Kingdom to the Global Fund, 2001-2025 (in GBP billion)



The donor withholds a portion of its funding to use for technical assistance related to the Global Fund.

The role of UK science

The UK is a global leader in scientific research and plays a critical role in global health efforts. UK science has been key in the fight against malaria, with UK institutions playing an important role in the development of the R21 and RTS,S malaria vaccines. Furthermore, the Innovative Vector Control Consortium and the London School of Hygiene & Tropical Medicine conducted years of research to develop mosquito nets using chlorfenapyr, a novel insecticide that helps combat insecticide-resistant mosquitoes. Clinical trials and pilot studies showed that these new nets improved malaria control by up to 50% in countries facing insecticide resistance. The Global Fund, Unitaaid and the U.S. President's Malaria Initiative have contributed to the deployment of millions of these new nets across sub-Saharan Africa. The UK has also developed several notable products used to treat drug-resistant TB.

Priority areas of our partnership

UK values and priorities are strongly mirrored in the Global Fund's model, strategy and investments.

Country ownership and inclusive governance

Countries where the Global Fund invests take the lead in determining how to best fight HIV, TB and malaria. Each implementing country has a Country Coordinating Mechanism (CCM), which submits funding applications to the Global Fund and oversees grants on behalf of their country. Each CCM includes stakeholders from the government, civil society, faith-based organizations, multilateral and bilateral donor agencies, nongovernmental organizations and the private sector. CCM membership must include local people living with and affected by the diseases and people from and representing key populations. The Global Fund model of inclusive governance ensures that civil society, communities, and people directly impacted by HIV, TB and malaria have an equal voice to governments in the decision-making process. This includes meaningful and empowered representation both in CCMs and on the Global Fund Board.

Strengthening health and community systems

The Global Fund is the world's largest multilateral grants provider for health and community systems. These investments support improved procurement and supply chains; strong data systems and data use; trained, qualified health care workers; stronger community responses and systems, including community health workers;

and the delivery of more integrated, people-centered health services so people can receive comprehensive care throughout their lives. Such investments are critical for progress against AIDS, TB, malaria and other infectious diseases. They are also vital in making progress towards universal health coverage and pandemic preparedness and response.

Gender equality and human rights

The Global Fund invests in treatment and prevention programs tailored for adolescent girls and young women, prevention of mother-to-child transmission of HIV, prevention of malaria during pregnancy, integrated screening and testing for sexually transmitted infections, economic empowerment programs, and gender-based violence interventions. The programs we support empower affected populations to know their health-related rights, mobilize around these rights and demand improved delivery of services, both in health facilities and in their communities.

Reaching the most vulnerable in humanitarian crises

Across multiple countries, including Ukraine, Afghanistan, Myanmar, Sudan and across the Sahel, the Global Fund partnership overcomes immense challenges to leave no one behind. Through our Emergency Fund, we have committed more than US\$154 million since 2014 to ensure continuity of existing services for HIV, TB and malaria. In Ukraine, the Global Fund has provided over US\$27 million in emergency funding to support HIV and TB treatment, prevention, and care, including

to internally displaced persons and hard-to-reach communities.

Accelerating equitable deployment of innovative tools

The Global Fund plays a critical role in accelerating the introduction and scale-up of innovative tools to fight HIV, TB and malaria. This includes supporting the deployment of promising new prevention options such as lenacapavir, a long-acting injectable for HIV, and dual active ingredient insecticide-treated nets, which offer enhanced protection against malaria. We also help drive down prices through our scale and market shaping: The annual cost of HIV treatment was US\$10,000 when the Global Fund was created, compared to as low as US\$35 today. We have also helped reduce prices for advanced TB drugs, and cut the average cost of malaria treatment by 39% since 2014.

Climate-health action

More frequent and extreme weather events impact the epidemiology and mortality of malaria, damage health facilities, wash away mosquito nets and medicines, and displace millions, often making it impossible to sustain long-term treatment regimens. The Global Fund supports countries in adapting and responding to these challenges by providing emergency funding after climate disasters and working to ensure more environmentally conscious supply management, climate-resilient health facilities and safe waste disposal. In the current grant cycle, 71% of Global Fund investments are dedicated to the 50 most climate-vulnerable countries.

Democratic Republic of the Congo: Digital Disease Surveillance Tools for Frontline Health Workers

The Democratic Republic of the Congo (DRC), Africa's second-largest country, faces major challenges in controlling infectious diseases due to decades of conflict and displacement, weak health systems, poor infrastructure, and favorable conditions for vector-borne illnesses. In the past decade, it has experienced numerous outbreaks of cholera, Ebola, measles, COVID-19, and mpox.



The Global Fund/Vincent Becker

To boost DRC's capacities to detect and respond to outbreaks and stop disease spread, the Global Fund and other partners are investing in the government's efforts to digitize the national disease reporting and early alert system.

The system begins in communities. Frontline health workers are trained to use a digital application to record new cases of infectious disease. Provincial authorities receive this data, combine it with data from other health districts and send to national health authorities at the Kinshasa-based National Centre for Epidemiological Intelligence.

Before this system existed, there were often delays of 2 to 3 weeks in sharing disease surveillance. Now, data is transmitted with the click of a button and health authorities can rapidly identify and respond to potential health threats.

United Kingdom: Championing global health through innovation and partnership

The United Kingdom has long been a global leader in health and development, leveraging its expertise, institutions and private sector to tackle the world's most pressing health challenges. British companies and foundations are at the forefront of efforts to strengthen health systems, drive digital transformation and build resilience against future pandemics. Through strategic partnerships and catalytic investments, the UK continues to play a vital role in advancing global health equity and innovation.

Anglo-American

The UK, through Anglo-American and in partnership with the Global Fund, has played a key role in advancing scalable digital health and AI readiness in Africa. The Digital Health Impact Accelerator (DHIA), launched in 2024, supports low- and middle-income countries in building digital public infrastructure – such as interoperability, data standards, electrification, and connectivity. Anglo-American's involvement has helped integrate AI and digital tools into public health systems in countries like South Africa, Zambia and Zimbabwe. DHIA's has connected health facilities across six African nations and

established the Health Tech Hub Africa in Kigali, including a Standards and Interoperability Lab for testing and certifying digital solutions. DHIA works with governments to strengthen digital governance and align with Africa Centres for Disease Control and Prevention and African Union procurement frameworks. By anchoring public-private partnerships, DHIA is enabling sustainable digital transformation and positioning African health systems for the future of AI-enabled care.

The Children's Investment Fund Foundation

The Children's Investment Fund Foundation (CIFF) has been a transformative partner of the Global Fund, particularly in the fight against HIV. Since 2014, CIFF has committed over US\$68 million, including support for pediatric HIV treatment in Zimbabwe and Kenya, and a US\$25 million investment to scale HIV self-testing across Africa – reaching over 12.4 million people by mid-2024. In 2022, CIFF pledged US\$33 million to expand access to PrEP and PEP, helping prevent new infections and strengthen digital health systems that now reach 7 million users. CIFF is also a partner in the scaled roll-out of lenacapavir, a long-acting injectable PrEP with up to 100% efficacy in trials. In 2025 CIFF committed a further US\$150 million to drive greater patient-centric services by supporting the scale-up of PrEP and HIV self-testing.

GSK/ViiV Healthcare

GSK and ViiV Healthcare have provided GBP 2 million to the Global Fund's Emergency Fund for Ukraine, supporting HIV and TB services amid the ongoing war. They are also long-standing champions of gender equality in health. Since 2018, ViiV has supported the HER Voice Fund, and in 2023, GSK and ViiV committed GBP 6 million to the Gender Equality Fund. This investment empowers women's organizations, strengthens community-led health responses, and advances gender-transformative policies.

Both companies are producing new products that are supporting the Global Fund to deliver on the partnership's mission to end the three diseases as public health threats. For example, the RTS,S malaria vaccine, developed by GSK, is the world's first malaria vaccine recommended by the WHO, shown to reduce

severe malaria and deaths in children by providing partial protection against *Plasmodium falciparum*, the deadliest malaria parasite. The highest impact of malaria vaccines will be achieved when introduced as part of a mix of WHO-recommended, lifesaving malaria prevention efforts that the Global Fund heavily invests in, like seasonal malaria chemoprevention and insecticide-treated mosquito nets.

Cabotegravir, developed by ViiV Healthcare, is a long-acting injectable used for both HIV treatment and prevention, offering sustained viral suppression, improved adherence and a preferred alternative to daily oral pills. The promise of this form of pre-exposure prophylaxis as part of a comprehensive approach to HIV prevention is becoming a reality, and the Global Fund is committed to expanding access to it.

About the Global Fund

The Global Fund is a worldwide partnership to defeat HIV, TB and malaria and ensure a healthier, safer, more equitable future for all. We raise and invest up to US\$5 billion a year to fight the deadliest infectious diseases, challenge the injustice that fuels them, and strengthen health systems and pandemic preparedness in more than 100 of the hardest hit countries. We unite world leaders, communities, civil society, health workers and the private sector to find solutions that have the most impact, and we take them to scale worldwide. Since 2002, the Global Fund partnership has saved 70 million lives.